» Articles » PMID: 15317667

Early Involvement of the Phosphatidylinositol 3-kinase/Akt Pathway in Lung Cancer Progression

Overview
Specialty Critical Care
Date 2004 Aug 20
PMID 15317667
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Signaling through the phosphatidylinositol 3-kinase (PI3-kinase) pathway has been associated with lung tumorigenesis. We examined the association between gene copy number of the PI3-kinase catalytic subunit alpha (PIK3CA) and phosphorylated Akt expression in invasive and preinvasive lung cancers. We sought to determine at what stage of tumor development gene copy number increase or phosphorylated Akt overexpression might affect tumor development. We assessed PIK3CA gene copy number by fluorescence in situ hybridization and expression of phosphorylated Akt by immunohistochemistry in 242 invasive and 43 preinvasive lung cancers and correlated our findings with clinical outcome. The PIK3CA was amplified in 70% of squamous carcinomas, 38% of large cell carcinomas, 19% of adenocarcinomas, and 67% of small cell lung cancers. Phosphorylated Akt overexpression was frequently observed, and strongly so in 12 to 17% of lung cancers depending on nuclear or cytoplasmic localization. Neither PIK3CA gene copy number nor phosphorylated Akt protein expression had prognostic significance. In preinvasive lesions, amplification of the PIK3CA and overexpression of phosphorylated Akt were associated with severe dysplasia and each other. These observations suggest frequent and early involvement of the PI3-kinase pathway in lung cancer.

Citing Articles

Ruthenium biochanin-A complex ameliorates lung carcinoma through the downregulation of the TGF-β/PPARγ/PI3K/TNF-α pathway in association with caspase-3-mediated apoptosis.

Cao M, Fan B, Zhen T, Das A, Wang J Toxicol Res. 2023; 39(3):455-475.

PMID: 37398567 PMC: 10313601. DOI: 10.1007/s43188-023-00177-1.


Chronic obstructive pulmonary disease alters the genetic landscape and tumor immune microenvironment in lung cancer patients.

Zhang Q, Feng X, Hu W, Li C, Sun D, Peng Z Front Oncol. 2023; 13:1169874.

PMID: 37388220 PMC: 10301745. DOI: 10.3389/fonc.2023.1169874.


AT7867 Inhibits the Growth of Colorectal Cancer Stem-Like Cells and Stemness by Regulating the Stem Cell Maintenance Factor Ascl2 and Akt Signaling.

Li Y, Yuan Y, Yang L, Chen H, Zhang X, Wen T Stem Cells Int. 2023; 2023:4199052.

PMID: 36824410 PMC: 9943616. DOI: 10.1155/2023/4199052.


Phase II Study of Taselisib in -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.

Krop I, Jegede O, Grilley-Olson J, Lauring J, Mitchell E, Zwiebel J JCO Precis Oncol. 2022; 6:e2100424.

PMID: 35138919 PMC: 8865530. DOI: 10.1200/PO.21.00424.


Pongol Methyl Ether Inhibits Akt and Suppresses Cancer Stem Cell Phenotypes in Lung Cancer Cells.

Silapech A, Racha S, Aksorn N, Lafauy P, Tungsukruthai S, Vinayanuwattikun C Pharmaceuticals (Basel). 2021; 14(11).

PMID: 34832867 PMC: 8624902. DOI: 10.3390/ph14111085.